Fulltext - SBU

Table 3.1.2.3 Effect of pneumococcal vaccination as prophylaxis in rAOM.AuthorYearReferenceCountryStudy designPatientpopulationInterventionControlvan Kempen et al2006[69]BelgiumRCTDouble-blindn=74Age: 1–7 yearsNumber of episodesAOM at inclusion:>2–3 AOM: n=17>4 AOM: n=577-valent PCV x 1–2 followedby booster with 23-valentPPV after 6–7 months:n=38Control (hepatitisA vaccine): n=36VT in 24 children,Ad was allowedVeenhoven et al2003[70]HollandRCTDouble-blindn=383Age: 1–7 years≥2/12 months AOM ratethe year preceding vaccinationStratified for age (12–24 monthsand 25–84 months) and forAOM rate (2–3 episodes and>3 episodes)7-valent PCV x 1–2(1 month interval) + PPV6–7 months later: n=190Control (HAV or HBV):n=193Eskola et al2001[201]FinlandRCTDouble-blindn=1 662Age: 2 monthsSubgroup analysis ofAOM-rate during follow-up:≥3 AOM episodes/6 months≥4 AOM episodes/12 months7-valent PCV x 4 (2, 4, 6,12 months of age): n=831HBV x 4: n=831Diagnoses were verifiedby myringotomy96Rörbehandling vid inflammation i mellanörat